| Website | galantos.com |
| Category | BioTech |
| Phone | +49 (0) 61 31 - 1 44 03 11 |
| Employees | |
| Founded | 2005 |
| TOTAL | $5.7M |
| VENTURE FUNDING TOTAL | $5.7M |
| Series C, 5/10 VRP Rhineland Palatinate Fund KfW Bankengruppe WFT Ventures High-Tech Gruenderfonds | $5.7M |
Galantos Pharma GmbH focuses on the development of drugs for the treatment of Alzheimer’s and other neurodegenerative diseases. It develops a drug for the treatment of mild-to-moderate Alzheimer’s dementia. The company develops a technology platform that is suitable for screening and preclinical validation of drug candidates that are acting on cholinergic and other neuro-receptors and on various brain enzymes. The company was founded in 2005 and is based in Mainz, Germany.
